• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Judge toss­es Am­gen's chal­lenge to Col­orado drug re­view board, says suit is 'too spec­u­la­tive'

2 months ago
Pharma
Law

At long last, No­var­tis’ ra­dio­phar­ma drug Plu­vic­to gets an ex­pand­ed la­bel

2 months ago
R&D
FDA+

FDA ap­proves Sanofi's RNAi drug for he­mo­phil­ia A and B

2 months ago
R&D
FDA+

J&J beats Vi­a­tris in patent fight over its an­tipsy­chot­ic drug, staving off com­pe­ti­tion

2 months ago
Pharma
Law

CHMP rec­om­mends sev­en la­bel ex­pan­sions and one new ap­proval, re­jects Lil­ly Alzheimer's drug

2 months ago
Pharma
FDA+

Mile­stone's shares dive af­ter FDA again re­jects drug for ab­nor­mal heart rhythm

2 months ago
Pharma
Manufacturing

DBV’s fi­nanc­ing for peanut al­ler­gy patch; Ei­sai di­vests pro­ton pump in­hibitor in Chi­na

2 months ago
News Briefing

Eu­ro­pean reg­u­la­tor re­jects Lil­ly's Alzheimer’s drug over po­ten­tial­ly fa­tal side ef­fects

2 months ago
Pharma
FDA+

BioN­Tech de­tails promis­ing mid-stage da­ta for its PD-L1xVEGF in ag­gres­sive lung can­cer

2 months ago
R&D

No­vo inks sec­ond obe­si­ty deal of the week, with Lex­i­con oral drug part­ner­ship worth up to $1B

2 months ago
Deals
Pharma

On the heels of staff cuts, CRISPR Ther­a­peu­tics COO de­parts; Changes ga­lore at Bi­cy­cle

2 months ago
Peer Review

Be­fore Alu­mis went pub­lic via IPO, it tried do­ing a re­verse merg­er with Ace­lyrin

2 months ago
Deals

Mer­ck KGaA pays Ab­bisko $85M for full com­mer­cial rights to be­nign tu­mor drug

2 months ago
Deals
R&D

FDA’s pol­i­cy, com­mu­ni­ca­tions staff like­ly to be among agency’s 3,500 staff cuts

2 months ago
FDA+
Law

Mer­ck de­tails in­jectable Keytru­da da­ta as it awaits au­tumn FDA de­ci­sion

2 months ago
R&D

Ex­clu­sive: Met­sera CEO on what it takes to build an obe­si­ty biotech in 2025

2 months ago
Startups
Pharma

With tar­iffs on the way, gener­ic drug­mak­ing woes could hin­der Trump’s reshoring plan 

2 months ago
Pharma
Manufacturing

Chiesi pours €430 in­to new Italy site; Bharat’s first CGT site in In­dia

2 months ago
Manufacturing

Equi­l­li­um says graft-ver­sus-host drug fails Phase 3, stock dives

2 months ago
R&D

What hap­pened to Mi­ga Health

2 months ago
Health Tech

Nkar­ta to lay off 34% of staff; Savara’s debt fi­nanc­ing deal

2 months ago
News Briefing

Kennedy an­nounces 10,000 job cuts at HHS, with ma­jor re­duc­tions ex­pect­ed at FDA, NIH and CDC

2 months ago
Pharma
FDA+

Why Mi­ga Health's co-founders de­cid­ed to quit build­ing

2 months ago
Deals
Health Tech

Fi­nan­cial re­turns and ef­fi­cien­cy of AI scribes re­main un­clear, re­port finds

2 months ago
AI
Health Tech
First page Previous page 22232425262728 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Confirm Profile

Endpoints News